Roche’s phase III EMPACTA study showed Actemra/RoActemra reduced the likelihood of needing mechanical ventilation in hospitalised patients with COVID-19 associated pneumonia

NEXT STORY
Roche launches new quantitative antibody test to measure SARS-CoV-2 antibodies, to support the evaluation of vaccines
PREV STORY
Junshi Biosciences Receives Orphan Drug Designation from the U.S. FDA for Toripalimab for the Treatment of Soft Tissue Sarcoma
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Global Clinical Trial Supplies Market Expected to Reach USD 2,092.5 Million By 2024: Zion Market Research

According to the report, global clinical trial supplies market was valued at approximately USD ...

author_avatar
NASDAQ Market News

Idera Pharmaceuticals Announces Acceptance of Several Abstracts related to the ILLUMINATE Tilsotolimod Clinical Development Program at the American Society of Clinical Oncology (ASCO) Meeting

author_avatar
NASDAQ Market News

Surface Oncology’s SRF617 Receives Orphan Drug Designation from FDA for Treatment of Pancreatic Cancer

author_avatar
NASDAQ Market News